Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 16 | 2024 | 1138 | 4.520 |
Why?
|
| Fluorodeoxyglucose F18 | 16 | 2024 | 142 | 4.010 |
Why?
|
| Lung Neoplasms | 19 | 2024 | 2394 | 4.000 |
Why?
|
| Positron-Emission Tomography | 13 | 2024 | 341 | 3.550 |
Why?
|
| Positron Emission Tomography Computed Tomography | 8 | 2024 | 100 | 3.400 |
Why?
|
| Multimodal Imaging | 7 | 2016 | 115 | 2.900 |
Why?
|
| Tumor Burden | 13 | 2023 | 314 | 2.680 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2016 | 2680 | 1.880 |
Why?
|
| Radiopharmaceuticals | 12 | 2022 | 193 | 1.750 |
Why?
|
| Whole Body Imaging | 7 | 2020 | 40 | 1.050 |
Why?
|
| Prognosis | 14 | 2024 | 3872 | 0.960 |
Why?
|
| Neoplasm Staging | 8 | 2022 | 2035 | 0.750 |
Why?
|
| Retrospective Studies | 12 | 2024 | 9703 | 0.550 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2018 | 693 | 0.550 |
Why?
|
| Machine Learning | 1 | 2020 | 298 | 0.550 |
Why?
|
| Aged | 17 | 2024 | 19943 | 0.540 |
Why?
|
| Models, Statistical | 1 | 2020 | 578 | 0.520 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 107 | 0.510 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 871 | 0.480 |
Why?
|
| Male | 24 | 2024 | 43925 | 0.480 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2023 | 1271 | 0.460 |
Why?
|
| Middle Aged | 15 | 2024 | 27030 | 0.440 |
Why?
|
| Female | 23 | 2024 | 47893 | 0.440 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6916 | 0.390 |
Why?
|
| Survival Rate | 5 | 2015 | 1927 | 0.390 |
Why?
|
| Humans | 30 | 2024 | 92337 | 0.380 |
Why?
|
| Radionuclide Imaging | 5 | 2018 | 217 | 0.360 |
Why?
|
| Risk Assessment | 3 | 2022 | 2369 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 187 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 866 | 0.330 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 72 | 0.320 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2007 | 1 | 0.290 |
Why?
|
| Echo-Planar Imaging | 1 | 2007 | 52 | 0.280 |
Why?
|
| Hypoxia, Brain | 1 | 2007 | 43 | 0.280 |
Why?
|
| Glutamine | 1 | 2007 | 95 | 0.270 |
Why?
|
| Glutamic Acid | 1 | 2007 | 155 | 0.270 |
Why?
|
| Cysts | 1 | 2007 | 103 | 0.260 |
Why?
|
| Brain Diseases | 1 | 2007 | 186 | 0.250 |
Why?
|
| Subtraction Technique | 4 | 2012 | 130 | 0.240 |
Why?
|
| Torso | 1 | 2023 | 14 | 0.210 |
Why?
|
| Adult | 7 | 2020 | 27532 | 0.210 |
Why?
|
| Bone and Bones | 3 | 2011 | 280 | 0.200 |
Why?
|
| Biological Transport | 2 | 2016 | 410 | 0.200 |
Why?
|
| Observer Variation | 3 | 2016 | 612 | 0.200 |
Why?
|
| Bone Neoplasms | 3 | 2011 | 313 | 0.200 |
Why?
|
| Neuroblastoma | 2 | 2018 | 391 | 0.200 |
Why?
|
| Lymphatic Metastasis | 3 | 2013 | 498 | 0.200 |
Why?
|
| Image Enhancement | 3 | 2011 | 562 | 0.180 |
Why?
|
| Brain | 2 | 2007 | 2352 | 0.170 |
Why?
|
| Random Allocation | 1 | 2020 | 328 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2794 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 2009 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2012 | 1511 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2012 | 608 | 0.140 |
Why?
|
| Reference Standards | 1 | 2018 | 144 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 1071 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1733 | 0.130 |
Why?
|
| Automation | 2 | 2015 | 112 | 0.130 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 21 | 0.130 |
Why?
|
| Young Adult | 3 | 2018 | 6624 | 0.130 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 37 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 987 | 0.130 |
Why?
|
| Prevalence | 2 | 2012 | 1294 | 0.120 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 87 | 0.120 |
Why?
|
| Glycolysis | 1 | 2016 | 184 | 0.120 |
Why?
|
| Isotretinoin | 1 | 2013 | 20 | 0.110 |
Why?
|
| Kinetics | 1 | 2016 | 1550 | 0.100 |
Why?
|
| Software | 2 | 2015 | 675 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1763 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2012 | 215 | 0.080 |
Why?
|
| Illinois | 1 | 2012 | 503 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 318 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2012 | 800 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 254 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 2 | 2011 | 222 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 115 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 9504 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2015 | 2978 | 0.070 |
Why?
|
| Pineal Gland | 1 | 2007 | 16 | 0.070 |
Why?
|
| Texas | 1 | 2007 | 126 | 0.070 |
Why?
|
| Protons | 1 | 2007 | 100 | 0.070 |
Why?
|
| Registries | 1 | 2012 | 902 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 234 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 316 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 660 | 0.060 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2006 | 139 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 334 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 471 | 0.050 |
Why?
|
| Time Factors | 1 | 2011 | 5430 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2368 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 23 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2517 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 69 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 58 | 0.040 |
Why?
|
| Biomarkers | 1 | 2007 | 1850 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 3218 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 20 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1398 | 0.030 |
Why?
|
| Risk Factors | 1 | 2007 | 5704 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 30 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 88 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2016 | 182 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1277 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 785 | 0.030 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 17 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 40 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 44 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 66 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 69 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 81 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 234 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 661 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1902 | 0.020 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2011 | 10 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3818 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 1956 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1503 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2007 | 57 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7334 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 220 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1576 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 2556 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 358 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 4468 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 8740 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1337 | 0.010 |
Why?
|